Parnax Lab
BSE: PARNAXLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Parnax Lab's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Parnax Lab Limited is an Indian pharmaceutical company specialising in the manufacturing and export of finished formulations, including liquid orals, ointments, and creams. The company operates through its subsidiary, Naman Pharma Drugs, serving both domestic and international markets across Africa, Southeast Asia, and the Middle East.
Business Model
The company operates as a niche player in the contract manufacturing and generic formulation space, focusing on cost-effective production and quality control. It leverages its manufacturing facilities in Gujarat to supply a diverse range of therapeutic categories to global markets.
Management Commentary
Management emphasises the expansion of the company's export footprint and the enhancement of manufacturing capabilities to meet the rising global demand for affordable healthcare solutions.
Growth Outlook
Growth is expected to be driven by the continued expansion of the firm's export presence and the scaling of its manufacturing operations to cater to international regulatory standards.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could restrict access to key export markets.
- Market Competition. The generic pharmaceutical sector is highly competitive, which may exert pressure on profit margins and pricing power.
- Geopolitical Risk. As an export-oriented firm, the company is susceptible to trade barriers and currency fluctuations in its primary markets across Africa and Southeast Asia.
Start your research today
Unlock AI insights, financials, peers and live data on Parnax Lab and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · consolidated
NET PROFIT
₹12 Cr
TTM · consolidated
EPS
₹10.27
TTM · consolidated
RETURN ON EQUITY
21.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-208.4%
TTM · standalone
P/E
11.0x
Q4 FY26 · consolidated
EV/EBITDA
4.8x
Q4 FY26 · consolidated
EBITDA MARGIN
50.2%
TTM · standalone
NET PROFIT MARGIN
220.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.8x
Q3 FY25 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Parnax LabPARNAXLAB | ₹148 Cr | 11.02 | 4.76 | -100.0% | 50.2% | 21.2% | -208.4% | -11.3% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Parnax Lab
BSE: PARNAXLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Parnax Lab's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Parnax Lab Limited is an Indian pharmaceutical company specialising in the manufacturing and export of finished formulations, including liquid orals, ointments, and creams. The company operates through its subsidiary, Naman Pharma Drugs, serving both domestic and international markets across Africa, Southeast Asia, and the Middle East.
Business Model
The company operates as a niche player in the contract manufacturing and generic formulation space, focusing on cost-effective production and quality control. It leverages its manufacturing facilities in Gujarat to supply a diverse range of therapeutic categories to global markets.
Management Commentary
Management emphasises the expansion of the company's export footprint and the enhancement of manufacturing capabilities to meet the rising global demand for affordable healthcare solutions.
Growth Outlook
Growth is expected to be driven by the continued expansion of the firm's export presence and the scaling of its manufacturing operations to cater to international regulatory standards.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could restrict access to key export markets.
- Market Competition. The generic pharmaceutical sector is highly competitive, which may exert pressure on profit margins and pricing power.
- Geopolitical Risk. As an export-oriented firm, the company is susceptible to trade barriers and currency fluctuations in its primary markets across Africa and Southeast Asia.
Start your research today
Unlock AI insights, financials, peers and live data on Parnax Lab and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · consolidated
NET PROFIT
₹12 Cr
TTM · consolidated
EPS
₹10.27
TTM · consolidated
RETURN ON EQUITY
21.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-208.4%
TTM · standalone
P/E
11.0x
Q4 FY26 · consolidated
EV/EBITDA
4.8x
Q4 FY26 · consolidated
EBITDA MARGIN
50.2%
TTM · standalone
NET PROFIT MARGIN
220.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.8x
Q3 FY25 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26